Abstract: Methods are disclosed utilizing the optically pure (−)-isomer of bupropion, which is a potent drug for treating depression, Parkinson's disease, obesity, weight gain and other disorders.

Abstract: This invention relates to the use of a compound of the formula wherein m, R1, R2, R3, R4, R5 and X are as defined in the disclosure, for treating or preventing migraine, depression and other disorders for which a 5-HT1 agonist or antagonist is indicated.

Abstract: The invention concerns the use of 1,6-dimethyl-8&bgr;-hydroxymethyl-10&agr;-methoxyergoline for preventing and/or treating motor neuron diseases.

Abstract: Methods and compositions are disclosed utilizing the optically pure (−) isomer of amlodipine. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the racemic mixture of amlodipine. The (−) isomer of amlodipine is also useful for the treatment of angina and such other conditions as may be related to the activity of (−) amlodipine as a calcium channel antagonist such as cerebral ischemia, cerebral disorders, arrhythmias, cardiac hypertrophy, coronary vasospasm, myocardial infarction, renal impairment and acute renal failure, without the concomitant liability of adverse effects associated with the racemic mixture of amlodipine.

Abstract: A composition and method for treating both superficial and subdermal inflammation is taught by treating an inflamed skin area, muscle, or bone joint, with a therapeutically effective amount of a skin-compatible ester of a zwitterionic aminosulphonic acid (ZASA-Ester) of the formula. ROCH2—CH2—N N—CH2CH2 SO3M wherein M is an alkali metal, like sodium, and R is a naturally occurring, straight-chain, saturated or unsaturated, aliphatic acid moiety, selected from one of the groups consisting of alkanes, alkenes, and alkadienes, each having a hydrocarbon chain of from one to twenty carbon atoms. The resulting HEPES esters are represented by the acetic acid ester as an exemplary alkane, the oleic acid ester as a exemplary alkene, and the linoleic acid ester as an exemplary alkadiene, the esters of which form fatty acids in nature. The most useful of which are the acetic oleic (cis isomer), linoleic, palmitic, and stearic moieties; they occur naturally as glycerides, i.e., esters of glycerol.

Abstract: Methods and compositions are disclosed utilizing the optically pure (−) isomer of amlodipine. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the racemic mixture of amlodipine. The (−) isomer of amlodipine is also useful for the treatment of angina and such other conditions as may be related to the activity of (−) amlodipine as a calcium channel antagonist such as cerebral ischemia, cerebral disorders, arrhythmias, cardiac hypertrophy, coronary vasospasm, myocardial infarction, renal impairment and acute renal failure, without the concomitant liability of adverse effects associated with the racemic mixture of amlodipine.

Abstract: Agonists of A2A adenosine receptors in combination with rolipram, its derivatives or other Type IV phosphodiesterase (PDE) inhibitors are effective for the treatment of restenosis.

Abstract: The present invention provides a method for treating pain using an atypical antipsychotic compound.

Abstract: A method of treating inflammatory skin diseases and/or hair loss, comprising administering to a patient in need of such treatment a therapeutically effective amount of a leukotriene receptor antagonist, an antihistamine, or other anti-inflammatory drug, preferably at least twice a day, preferably for at least two months.

Abstract: The present invention provides a therapeutic agent for dermatitis, particularly a therapeutic agent for atopic dermatitis, which is very safe and which shows few adverse side-effects in comparison to, for example, steroidal agents. The present invention relates to a therapeutic agent containing a compound represented by the following formula (I) or a pharmaceutically acceptable salt or hydrate thereof as an effective ingredient: wherein R is hydrogen or a halogen. The therapeutic agent for dermatitis according to the present invention effectively and in a dose-dependent manner suppresses antigen-induced swelling in a mouse ear, a recognized animal model for atopic dermatitis, and suppresses the antigen-induced flare-up reaction in mice which occurred with the swelling reaction. In addition, no adverse reaction in the skin are observed.

Abstract: The invention features methods of using pharmaceutically-active 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzthiazoles and derivatives.

Abstract: The present invention provides methods of promoting synthesis of nitric oxide or endothelium-derived relaxing factor (EDRF) in hypoxic mammalian tissues by administering at least one N-hydroxyguanidine compound that is a substrate of nitric oxide synthase, and, optionally, one or more vasoactive agents and/or thromboxane A2 receptor antagonists. The present invention also provides methods of promoting vasorelaxation and treating sexual dysfunctions in patients by administering at least one N-hydroxyguanidine compound that is a substrate for nitric oxide synthase, and, optionally, at least one vasoactive agent and/or thromboxane A2 receptor antagonist. The present invention also provides methods for treating clinical conditions resulting from hypoxic conditions such as pulmonary disease, cardiovascular disorders, circulatory hypoxia, specific organ hypoxia, localized hypoxia, edema, central nervous system disorders, memory loss, or arterial disease.

Abstract: The present invention relates to the use of &ggr;-hydroxybutyric acid amides in the treatment of drug addiction and alcoholism, more particularly in reducing chronic alcoholics' desire for and habit of consuming alcoholic drinks and in the treatment of the syndrome of abstinence from alcohol.

Abstract: A process for reducing the body weight of overweight humans and domestic animals, such as dogs and cats, by administering creatine is provided. Creatine is administered at a daily dose of 0.15 mg-15 mg per kilogram of body weight by various methods, including oral administration, injection, infusion, and suppositories for rectal application. Also provided is the use of creatine for manufacturing a medicament containing creatine that can be administered by the process of the invention.

Abstract: A corticotropin releasing factor (CRF) antagonist is administered to treat disorders that can be treated by altering circadian rhythm.

Abstract: The present invention relates to a neurotrophic factor secretagogue, in particular, to a BDNF (brain-derived neurotrophic factor) secretagogue, which comprises as an active ingredient an NO donor. The medicament of the present invention promotes the secretion of neurotrophic factors from mammalian central neural cells. Thus, the medicament of the present invention, i.e., NO donor, is possibly applicable to the treatment of diseases caused by neutrotrophic factors, for example, neurodegenerative diseases, and is expected to exhibit the efficacious effects thereon. Also, the present invention provides a novel medication for neurodegenerative diseases.

Abstract: A method of treatment of seborrheic dermatitis includes the application, in the form of either a lotion or a cream, of a mixture including a therapeutically effective amount of ivermectin in water preferably in a concentration of about 750 micrograms per milliliter (mcg/ml), in the case of a lotion, and with a pharmaceutically acceptable carrier if used as a cream. Such a lotion or cream is applied nightly preferably for a period of seven days and then employed on a maintenance basis one to four times per month.

Abstract: This invention relates to enema and enterically-coated dosage forms having an amount of azathioprine effective to prevent colorectal adenomas without dose-limiting systemic toxicity.

Abstract: A method of treating and/or preventing congestion associated with allergic and inflammatory conditions of the upper and lower airway passages in a human, by administering an amount of desloratadine effective for such treating and/or preventing.

Abstract: Topical compositions which include urea and an antimicrobial agent, particularly sulfacetamide, are described. Sulfacetamide compositions further including sulfur are also described. Methods for treating dermatological disorders using the compositions are also described.